Literature DB >> 31989476

Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.

Dong Hyun Kim1, Han Sol Lee1, Tae-Wan Kwon1, Young-Min Han1, Nae-Won Kang2, Mee Yeon Lee3, Dae-Duk Kim2, Myeong Gyu Kim4, Jae-Young Lee5.   

Abstract

The term "single enzyme nanoparticle" (SEN) refers to a chemically or biologically engineered single enzyme molecule. SENs are distinguished from conventional protein nanoparticles in that they can maintain their individual structure and enzymatic activity following modification. Furthermore, SENs exhibit enhanced properties as biopharmaceuticals, such as reduced antigenicity, and increased stability and targetability, which are attributed to the introduction of specific moieties, such as poly(ethylene glycol), carbohydrates, and antibodies. Enzyme replacement therapy (ERT) is a crucial therapeutic option for controlling enzyme-deficiency-related disorders. However, the unfavorable properties of enzymes, including immunogenicity, lack of targetability, and instability, can undermine the clinical significance of ERT. As shown in the cases of Adagen®, Revcovi®, Palynziq®, and Strensiq®, SEN can be an effective technology for overcoming these obstacles. Based on these four licensed products, we expect that additional SENs will be introduced for ERT in the near future. In this article, we review the concepts and features of SENs, as well as their preparation methods. Additionally, we summarize different types of enzyme deficiency disorders and the corresponding therapeutic enzymes. Finally, we focus on the current status of SENs in ERT by reviewing FDA-approved products.

Entities:  

Keywords:  Biologics; Enzyme deficiency; Enzyme replacement therapy; Enzyme therapeutics; Single enzyme nanoparticle

Year:  2020        PMID: 31989476      PMCID: PMC7125423          DOI: 10.1007/s12272-020-01216-3

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  33 in total

Review 1.  Multiple biological activities of curcumin: a short review.

Authors:  Radha K Maheshwari; Anoop K Singh; Jaya Gaddipati; Rikhab C Srimal
Journal:  Life Sci       Date:  2006-01-18       Impact factor: 5.037

2.  A new protocol for predicting novel GSK-3β ATP competitive inhibitors.

Authors:  Jiansong Fang; Dane Huang; Wenxia Zhao; Hu Ge; Hai-Bin Luo; Jun Xu
Journal:  J Chem Inf Model       Date:  2011-06-09       Impact factor: 4.956

3.  The anesthetic action of some polyhalogenated ethers-Monte Carlo method based QSAR study.

Authors:  Mlađan Golubović; Milan Lazarević; Dragan Zlatanović; Dane Krtinić; Viktor Stoičkov; Bojan Mladenović; Dragan J Milić; Dušan Sokolović; Aleksandar M Veselinović
Journal:  Comput Biol Chem       Date:  2018-04-13       Impact factor: 2.877

4.  3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.

Authors:  Li Gao; Mian Zu; Song Wu; Ai-Lin Liu; Guan-Hua Du
Journal:  Bioorg Med Chem Lett       Date:  2011-07-26       Impact factor: 2.823

5.  Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice.

Authors:  Lili Chen; Jie Dou; Zhenzhen Su; Huimin Zhou; Hui Wang; Weidong Zhou; Qinglong Guo; Changlin Zhou
Journal:  Antiviral Res       Date:  2011-07-18       Impact factor: 5.970

Review 6.  Toward a universal influenza virus vaccine: prospects and challenges.

Authors:  Natalie Pica; Peter Palese
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

Review 7.  The pathology of influenza virus infections.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

8.  Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.

Authors:  Han-Gil Cho; Jang-Hoon Choi; Hyun-Kyung Lee; Su-Kyoung Mun; Jong-Bok Lee; Eek-Hoon Jho; Chun Kang; Young-Hee Lim
Journal:  Arch Virol       Date:  2013-05-21       Impact factor: 2.574

Review 9.  A "universal" human influenza A vaccine.

Authors:  W Fiers; M De Filette; A Birkett; S Neirynck; W Min Jou
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

10.  3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors.

Authors:  Pallav D Patel; Maulik R Patel; Neerja Kaushik-Basu; Tanaji T Talele
Journal:  J Chem Inf Model       Date:  2007-12-13       Impact factor: 4.956

View more
  2 in total

Review 1.  Lysosome (Dys)function in Atherosclerosis-A Big Weight on the Shoulders of a Small Organelle.

Authors:  André R A Marques; Cristiano Ramos; Gisela Machado-Oliveira; Otília V Vieira
Journal:  Front Cell Dev Biol       Date:  2021-03-29

2.  HexA-Enzyme Coated Polymer Nanoparticles for the Development of a Drug-Delivery System in the Treatment of Sandhoff Lysosomal Storage Disease.

Authors:  Eleonora Calzoni; Alessio Cesaretti; Nicolò Montegiove; Alessandro Di Michele; Roberto Maria Pellegrino; Carla Emiliani
Journal:  J Funct Biomater       Date:  2022-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.